MCID: MCR088
MIFTS: 51

Microscopic Polyangiitis

Categories: Rare diseases, Neuronal diseases, Cardiovascular diseases, Nephrological diseases, Respiratory diseases, Bone diseases

Aliases & Classifications for Microscopic Polyangiitis

MalaCards integrated aliases for Microscopic Polyangiitis:

Name: Microscopic Polyangiitis 50 56
Microscopic Polyarteritis 56 69
Micropolyangiitis 56
Mpa 56

Characteristics:

Orphanet epidemiological data:

56
microscopic polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Germany),1-9/1000000 (Norway),1-9/100000 (United Kingdom),1-9/100000 (Germany),1-9/100000 (Australia),1-9/100000 (Japan),1-9/100000 (Kuwait),1-9/1000000 (Canada),1-9/100000 (Greece),1-9/1000000 (Lithuania),1-9/100000 (Sweden); Age of onset: Adult; Age of death: adult;

Classifications:



Summaries for Microscopic Polyangiitis

NIH Rare Diseases : 50 microscopic polyangiitis (mpa) is a disorder that causes blood vessel inflammation (vasculitis), which can lead to organ damage. the kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. mpa is diagnosed in people of all ages, all ethnicities, and both genders. the cause of this disorder is unknown. last updated: 8/13/2014

MalaCards based summary : Microscopic Polyangiitis, also known as microscopic polyarteritis, is related to systemic lupus erythematosus and rheumatoid arthritis, and has symptoms including renal insufficiency, sinusitis and epistaxis. An important gene associated with Microscopic Polyangiitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Azathioprine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and neutrophil.

Wikipedia : 72 Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune,... more...

Related Diseases for Microscopic Polyangiitis

Diseases related to Microscopic Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
id Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 28.8 HLA-DRB1 MPO TNF
2 rheumatoid arthritis 28.7 HLA-B HLA-DRB1 TNF
3 goodpasture syndrome 28.4 HLA-B KIR3DL1 TNF
4 vasculitis 11.3
5 anca-associated vasculitis 11.2
6 autoimmune oophoritis 10.4 MPO TNF
7 uveitis 10.4 MPO TNF
8 dermatomycosis 10.4 MPO TNF
9 facial dermatosis 10.4 MPO TNF
10 biemond syndrome 10.4 HLA-DRB1 TNF
11 arthus reaction 10.4 MPO TNF
12 mosaic trisomy 1 10.4 HLA-DRB1 TNF
13 pericholangitis 10.4 MPO TNF
14 autoimmune retinopathy 10.4 HLA-DRB1 TNF
15 gastroduodenal crohn's disease 10.4 MPO TNF
16 epstein-barr virus hepatitis 10.4 HLA-DRB1 TNF
17 glioblastoma multiforme 10.4 MPO TNF
18 limb-body wall complex 10.4 HLA-DRB1 TNF
19 moved to 244450 10.4 HLA-DRB1 TNF
20 kernicterus due to isoimmunization 10.4 HLA-DRB1 TNF
21 riboflavin transporter deficiency 10.3 HLA-DRB1 TNF
22 lymphocytic colitis 10.3 HLA-DRB1 TNF
23 louping ill 10.3 MPO TNF
24 hepadnavirus infection 10.3 HLA-DRB1 TNF
25 polyarteritis nodosa 10.3
26 endocervical type cervical mucinous adenocarcinoma 10.3 MPO TNF
27 moderately severe hemophilia b 10.3 HLA-DRB1 TNF
28 patau syndrome 10.3 HLA-DRB1 TNF
29 plummer's disease 10.3 HLA-DRB1 TNF
30 endogenous depression 10.3 HLA-DRB1 TNF
31 mixed lacrimal gland cancer 10.3 MPO TNF
32 extrahepatic bile duct adenocarcinoma 10.3 HLA-DRB1 TNF
33 iida kannari syndrome 10.3 HLA-DRB1 TNF
34 ramsay hunt syndrome i 10.3 HLA-B HLA-DRB1
35 pericardium disease 10.3 HLA-DRB1 TNF
36 ragweed sensitivity 10.3 MPO TNF
37 idiopathic subglottic tracheal stenosis 10.3 HLA-B HLA-DRB1
38 pulmonary hemosiderosis 10.3 HLA-DRB1 TNF
39 hernia of ovary and fallopian tube 10.3 HLA-B HLA-DRB1
40 progressive myoclonus epilepsy 10.3 HLA-B HLA-DRB1
41 endometrial clear cell adenocarcinoma 10.3 MPO TNF
42 dentinogenesis imperfecta 10.3 HLA-DRB1 TNF
43 left bundle branch hemiblock 10.3 HLA-DRB1 TNF
44 mazabraud syndrome 10.2 HLA-B HLA-DRB1
45 nasal cavity carcinoma in situ 10.2 MPO TNF
46 acanthoma 10.2 HLA-B HLA-DRB1
47 acute chest syndrome 10.2 MPO TNF
48 mesenchymal cell neoplasm 10.2 HLA-DRB1 TNF
49 churg-strauss syndrome 10.2
50 antigen-peptide-transporter 2 deficiency 10.2 HLA-B TNF

Graphical network of the top 20 diseases related to Microscopic Polyangiitis:



Diseases related to Microscopic Polyangiitis

Symptoms & Phenotypes for Microscopic Polyangiitis

Human phenotypes related to Microscopic Polyangiitis:

56 32 (show all 37)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 56 32 hallmark (90%) Very frequent (99-80%) HP:0000083
2 sinusitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000246
3 epistaxis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000421
4 uveitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000554
5 hematuria 56 32 hallmark (90%) Very frequent (99-80%) HP:0000790
6 cutis marmorata 56 32 occasional (7.5%) Occasional (29-5%) HP:0000965
7 skin rash 56 32 hallmark (90%) Very frequent (99-80%) HP:0000988
8 arthritis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001369
9 subcutaneous nodule 56 32 occasional (7.5%) Occasional (29-5%) HP:0001482
10 congestive heart failure 56 32 occasional (7.5%) Occasional (29-5%) HP:0001635
11 pericarditis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001701
12 pancreatitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001733
13 subcutaneous hemorrhage 56 32 frequent (33%) Frequent (79-30%) HP:0001933
14 fever 56 32 hallmark (90%) Very frequent (99-80%) HP:0001945
15 diarrhea 56 32 frequent (33%) Frequent (79-30%) HP:0002014
16 nausea and vomiting 56 32 frequent (33%) Frequent (79-30%) HP:0002017
17 abdominal pain 56 32 frequent (33%) Frequent (79-30%) HP:0002027
18 hemoptysis 56 32 hallmark (90%) Very frequent (99-80%) HP:0002105
19 gastrointestinal hemorrhage 56 32 frequent (33%) Frequent (79-30%) HP:0002239
20 peritonitis 56 32 frequent (33%) Frequent (79-30%) HP:0002586
21 vasculitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0002633
22 arthralgia 56 32 frequent (33%) Frequent (79-30%) HP:0002829
23 autoimmunity 56 32 hallmark (90%) Very frequent (99-80%) HP:0002960
24 myalgia 56 32 frequent (33%) Frequent (79-30%) HP:0003326
25 paresthesia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003401
26 venous thrombosis 56 32 frequent (33%) Frequent (79-30%) HP:0004936
27 gastrointestinal infarctions 56 32 frequent (33%) Frequent (79-30%) HP:0005244
28 abnormality of the retinal vasculature 56 32 occasional (7.5%) Occasional (29-5%) HP:0008046
29 erythema 56 32 hallmark (90%) Very frequent (99-80%) HP:0010783
30 arrhythmia 56 32 occasional (7.5%) Occasional (29-5%) HP:0011675
31 oliguria 56 32 hallmark (90%) Very frequent (99-80%) HP:0100520
32 episcleritis 56 32 occasional (7.5%) Occasional (29-5%) HP:0100534
33 gangrene 56 32 occasional (7.5%) Occasional (29-5%) HP:0100758
34 glomerulopathy 56 32 hallmark (90%) Very frequent (99-80%) HP:0100820
35 skin ulcer 56 32 frequent (33%) Frequent (79-30%) HP:0200042
36 peripheral neuropathy 56 Occasional (29-5%)
37 increased inflammatory response 56 Very frequent (99-80%)

Drugs & Therapeutics for Microscopic Polyangiitis

Drugs for Microscopic Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
alemtuzumab Approved, Investigational Phase 4 216503-57-0
4
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
8
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
9
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
10
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
12
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
13 Alkylating Agents Phase 4,Phase 3,Phase 2
14 Antimetabolites Phase 4,Phase 3,Phase 2
15 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
20 Dermatologic Agents Phase 4,Phase 3,Phase 2
21 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
23 Vitamin B Complex Phase 4,Phase 3,Phase 2
24 Antiemetics Phase 4,Phase 2,Phase 3
25 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
26 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
27 Autonomic Agents Phase 4,Phase 2,Phase 3
28 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
29 glucocorticoids Phase 4,Phase 2,Phase 3
30 Hormone Antagonists Phase 4,Phase 2,Phase 3
31 Hormones Phase 4,Phase 2,Phase 3
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
33 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
34 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3
35 Neuroprotective Agents Phase 4,Phase 2,Phase 3
36 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
37 Prednisolone acetate Phase 4,Phase 2,Phase 3
38 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3
39 Prednisolone phosphate Phase 4,Phase 2,Phase 3
40 Protective Agents Phase 4,Phase 2,Phase 3
41 Tin Fluorides Phase 4
42 Folate Nutraceutical Phase 4,Phase 3,Phase 2
43 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2
44
belimumab Approved Phase 3 356547-88-1 5957 10451420
45 Dexchlorpheniramine Experimental Phase 3 25523-97-1
46 Antibodies Phase 3,Phase 2
47 Antibodies, Antineutrophil Cytoplasmic Phase 3,Phase 2
48 Immunoglobulins Phase 3,Phase 2
49 Plasma Substitutes Phase 3
50 gamma-Globulins Phase 3

Interventional clinical trials:

(show all 50)

id Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
3 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
4 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Recruiting NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
5 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
6 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Active, not recruiting NCT02169219 Phase 4 Glucocorticoids;Rituximab
7 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
8 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
9 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
10 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
11 Belimumab in Remission of VASculitis Completed NCT01663623 Phase 3 Azathioprine
12 Efficacy Study of Two Treatments in the Remission of Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
13 Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
14 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Active, not recruiting NCT00987389 Phase 3 Glucocorticoids
15 Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Active, not recruiting NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
16 Rituximab Vasculitis Maintenance Study Active, not recruiting NCT01697267 Phase 3 Azathioprine
17 Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
18 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
19 Plasma Exchange for Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
20 IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
21 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
22 Anti-Cytokine Therapy for Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
23 Steroids and Methotrexate to Treat Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
24 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Active, not recruiting NCT01750697 Phase 2 Rituximab
25 Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
26 BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
27 CellCept in p-ANCA Vasculitis Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
28 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1
29 PRO Development for ANCA Associated Vasculitis Unknown status NCT01729624
30 An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01613599 Rituximab
31 RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Completed NCT00307593 Infliximab;Rituximab
32 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
33 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
34 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
35 Impact of Vasculitis on Employment and Income Completed NCT02476292
36 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
37 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
38 Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis Recruiting NCT00315393
39 Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis Recruiting NCT02474888
40 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Recruiting NCT01066208
41 Pediatric Vasculitis Initiative Recruiting NCT02006134
42 One-Time DNA Study for Vasculitis Recruiting NCT01241305
43 VCRC Tissue Repository Recruiting NCT02967068
44 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
45 Vasculitis Pregnancy Registry Recruiting NCT02593565
46 Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) Recruiting NCT01862068
47 VCRC Patient Contact Registry Patient-Reported Data Validation Study Enrolling by invitation NCT02190942
48 Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Not yet recruiting NCT02126098
49 Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. Not yet recruiting NCT03290456 Prednisone 5mg/day extended of 9 additional months;Placebo 5mg/day extended of 9 additionnal months.
50 Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Terminated NCT01586858

Search NIH Clinical Center for Microscopic Polyangiitis

Genetic Tests for Microscopic Polyangiitis

Anatomical Context for Microscopic Polyangiitis

MalaCards organs/tissues related to Microscopic Polyangiitis:

39
Skin, Lung, Neutrophil, Kidney, Bone, Heart, Breast

Publications for Microscopic Polyangiitis

Articles related to Microscopic Polyangiitis:

(show top 50) (show all 401)
id Title Authors Year
1
Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis. ( 28569178 )
2017
2
Noninfective endocarditis in microscopic polyangiitis: Report of a case with a successful response to immunosuppressive therapy. ( 28822626 )
2017
3
IgM Antibodies to Proteinase 3 in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. ( 28076879 )
2017
4
Phlebectasia in a finger in a case of microscopic polyangiitis with peripheral polyneuropathy. ( 28838824 )
2017
5
Severe microscopic polyangiitis with unilateral vocal cord paralysis as initial manifestation. ( 28559644 )
2017
6
A case of inclusion body myositis complicated by microscopic polyangiitis. ( 28726537 )
2017
7
Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. ( 28539536 )
2017
8
Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. ( 28905856 )
2017
9
The effect and possible clinical efficacy of in vivo inhibition of neutrophil extracellular traps by blockade of PI3K-gamma on the pathogenesis of microscopic polyangiitis. ( 28880680 )
2017
10
Differential Expression of Toll-Like Receptor Signaling Pathway Is Associated with Microscopic Polyangiitis in Peripheral Blood Neutrophils. ( 28375762 )
2017
11
Elevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis. ( 28616269 )
2017
12
Gallbladder bleeding associated with microscopic polyangiitis: a case report. ( 28852465 )
2017
13
Concurrent Double Fungal Infections of the Skin Caused by Phialemoniopsis endophytica and Exophiala jeanselmei in a Patient with Microscopic Polyangiitis. ( 28654130 )
2017
14
Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. ( 28422001 )
2017
15
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. ( 28733791 )
2017
16
Myeloperoxidase/HLA Class II Complexes Recognized by Autoantibodies in Microscopic Polyangiitis. ( 28575531 )
2017
17
A tale of two vasculitides: biopsy-proven giant cell arteritis followed by the independent development of renal-limited microscopic polyangiitis. ( 28432167 )
2017
18
Microscopic polyangiitis: Atypical presentation with extensive small bowel necrosis, diffuse alveolar hemorrhage, and renal failure. ( 28348948 )
2017
19
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis with Polyangiitis, Microscopic Polyangiitis or Polyarteritis Nodosa without Poor Prognosis Factors A Randomized-Controlled Trial. ( 28678392 )
2017
20
The influence of the Great East Japan earthquake on microscopic polyangiitis: A retrospective observational study. ( 28498830 )
2017
21
Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: A retrospective single-center study. ( 27400379 )
2016
22
Ultra-Wide-Field Fluorescein Angiography in Microscopic Polyangiitis. ( 27872779 )
2016
23
Myeloperoxidase anti-neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis. ( 26833773 )
2016
24
Presence of Citrullinated Histone H3-Positive Neutrophils in Microscopic Polyangiitis from the Early Phase: An Autopsy Proven Case. ( 27427341 )
2016
25
Paraneoplastic microscopic polyangiitis presenting after thymectomy. ( 27222874 )
2016
26
Central nervous system vasculitis in pediatric microscopic polyangiitis: A case report and review of literature. ( 27156236 )
2016
27
Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients. ( 27169414 )
2016
28
Microscopic polyangiitis presenting with multiple punched-out ulcers: A case report. ( 27177686 )
2016
29
Comparing presenting clinical features of 48 children with microscopic polyangiitis (MPA) against 183 having granulomatosis with polyangiitis (GPA). An ARChiVe study. ( 27111558 )
2016
30
Microscopic polyangiitis complicated with bilateral brachial plexopathy: a case report and review of the literature. ( 26782370 )
2016
31
Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). ( 26970486 )
2016
32
Bilateral Scleritis and Retinal Vasculitis in Microscopic Polyangiitis. ( 27871395 )
2016
33
Acute cervical myelitis and microscopic polyangiitis. ( 27158038 )
2016
34
Pulmonary Microscopic Polyangiitis Presenting as Acute Respiratory Failure from Diffuse Alveolar Hemorrhage. ( 26847106 )
2016
35
Development of intracerebral hemorrhage in the short-term clinical course of a patient with microscopic polyangiitis without neurological symptoms at diagnosis: an autopsy case. ( 28508972 )
2016
36
Very early renal relapse of microscopic polyangiitis after kidney transplantation. ( 27118023 )
2016
37
Successful Immunosuppressive Treatment of Mixed Connective Tissue Disease Complicated by Microscopic Polyangiitis. ( 27238624 )
2016
38
Microscopic polyangiitis with crescentic glomerulonephritis initially presenting as acute pancreatitis. ( 26864299 )
2016
39
Early interstitial lung disease in microscopic polyangiitis: Case report and literature review. ( 27919708 )
2016
40
[Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis]. ( 26346417 )
2016
41
Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. ( 27770813 )
2016
42
Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. ( 26934300 )
2016
43
Microscopic Polyangiitis with Spinal Cord Involvement: A Case Report and Review of the Literature. ( 27068775 )
2016
44
Diagnosis of perinuclear anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis in silicotics: case report. ( 27186376 )
2016
45
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. ( 27097593 )
2016
46
Chronic and Asymptomatic Diffuse Alveolar Haemorrhage with Microscopic Polyangiitis: A Case Report and Review of the Literature. ( 28050304 )
2016
47
Protective Role of HLA-DRB1*13:02 against Microscopic Polyangiitis and MPO-ANCA-Positive Vasculitides in a Japanese Population: A Case-Control Study. ( 27166610 )
2016
48
Microscopic polyangiitis preceded by combined pulmonary fibrosis and emphysema. ( 26236623 )
2015
49
Hemocholecyst complicated in a hemodialysis patient with microscopic polyangiitis. ( 25671404 )
2015
50
Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. ( 26297628 )
2015

Variations for Microscopic Polyangiitis

Expression for Microscopic Polyangiitis

Search GEO for disease gene expression data for Microscopic Polyangiitis.

Pathways for Microscopic Polyangiitis

Pathways related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 HLA-B HLA-DRB1 KIR3DL1 KIR3DS1 MPO TNF
2
Show member pathways
12.99 HLA-B HLA-DRB1 KIR3DL1 KIR3DS1
3
Show member pathways
12.35 HLA-B HLA-DRB1 TNF
4
Show member pathways
12.09 HLA-B KIR3DL1 TNF
5 11.99 HLA-B HLA-DRB1 TNF
6
Show member pathways
11.66 HLA-B HLA-DRB1 KIR3DL1 TNF
7 11.51 HLA-DRB1 TNF
8 11.51 HLA-B HLA-DRB1 MPO
9 11.45 HLA-DRB1 TNF
10 11.26 HLA-B KIR3DL1 KIR3DS1
11 11.14 MPO TNF
12 10.85 HLA-DRB1 TNF
13 10.46 MPO TNF

GO Terms for Microscopic Polyangiitis

Cellular components related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.46 HLA-B KIR3DL1 KIR3DS1 TNF
2 ER to Golgi transport vesicle membrane GO:0012507 8.96 HLA-B HLA-DRB1
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.62 HLA-B HLA-DRB1

Biological processes related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 9.26 HLA-B HLA-DRB1
2 antigen processing and presentation GO:0019882 9.16 HLA-B HLA-DRB1
3 immune response GO:0006955 9.02 HLA-B HLA-DRB1 KIR3DL1 KIR3DS1 TNF
4 negative regulation of growth of symbiont in host GO:0044130 8.96 MPO TNF

Molecular functions related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.62 HLA-B HLA-DRB1

Sources for Microscopic Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....